PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611 Posted on January 16, 2025January 15, 2026 by edgover
Pulsesight seeks clinical trial clearance for PST-611 for dry AMD/geographic atrophy Posted on January 14, 2025January 18, 2026 by edgover
Data support transferrin vectorised therapy for geographic atrophy Posted on November 11, 2024January 18, 2026 by edgover
PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board Posted on April 9, 2024January 18, 2026 by edgover
PulseSight launches with gene therapy platform targeting age-related blindness Posted on March 4, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches with focus on non-viral gene therapies Posted on February 29, 2024January 18, 2026 by edgover
PulseSight Therapeutics Launches With Age-Related Macular Disease Gene Therapy Pipeline Posted on February 28, 2024January 18, 2026 by edgover
PulseSight Therapeutics launches to advance non-viral gene therapies Posted on February 28, 2024January 18, 2026 by edgover
[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding Posted on February 28, 2024January 18, 2026 by edgover
![[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding](https://pulsesight.com/wp-content/uploads/2026/01/Paris-based-PulseSight-Therapeutics-Secures-an-Undisclosed-amount-in-Seed-Funding.webp)